TED · VERIFIED SOURCE
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Interferon beta-1a (ausschließlich zur subkutanen Anwendung), ATC L03AB07 f. d. Z. 01.11.26-31.10.28
DAK-Gesundheit · Germany · Hamburg
BUSINESS NEED
Opportunity details
Procurement notice published by DAK-Gesundheit.
BUYER
DAK-Gesundheit
Open the buyer profile to see mapped decision responsibilities and other active needs.
View buyer profile